What's the difference between a CRO and a VP of Sales for a healthcare technology company?

This vs. the common alternatives

The healthcare technology market gives you four realistic revenue-leadership structures, and most companies pick the wrong one because they hire for the pain they feel this quarter rather than the constraint that is actually binding. Knowing what each structure does — and what it cannot do — is the entire practical difference between a CRO and a VP of Sales here.

Structure one: VP of Sales only. This is the right answer when your product-market fit is already proven inside a defined buyer segment, your compliance posture is settled (SOC 2 in hand, HIPAA program documented, a standard business associate agreement your counsel will actually sign), and your problem is throughput — you have more demand than you can work. A VP of Sales owns rep hiring, territory design, quota setting, pipeline hygiene, forecast accuracy, and deal coaching. In a healthcare tech company that has cleared the regulatory hurdles, a strong VP of Sales can take a team from four reps to twenty-five and hold attainment above 70 percent. What this structure cannot do is change what you sell, how it is priced against a value-based contract, or whether a health plan will reimburse it. Those are upstream of sales, and asking a VP of Sales to fix them is asking someone to renegotiate the physics of the deal.

Structure two: CRO only, no VP of Sales underneath. Common in seed and Series A healthcare tech, where the CRO is a player-coach carrying a personal number while also building the function. This works below roughly eight to twelve reps. Past that, the CRO's time gets consumed by day-to-day deal desk and one-on-ones, and the strategic work — payer conversations, evidence strategy, channel partnerships with EHR vendors — silently stops. The tell is a CRO whose calendar is 80 percent internal.

Structure three: CRO with a VP of Sales reporting in. The mature shape, typically at 15 million to 30 million ARR and up in healthcare tech, though the trigger is complexity rather than revenue. You need it when you sell through more than one motion — direct to health systems, plus a channel through an EHR marketplace, plus an enterprise payer or employer-benefits motion. The VP of Sales owns the direct engine end to end. The CRO owns everything that decides whether that engine has fuel: pricing and packaging, marketing pipeline, customer success and net revenue retention, partnerships, and the clinical-evidence roadmap that unlocks segments the direct team cannot open alone.

Structure four: fractional or interim CRO plus an existing VP of Sales. Often the highest-leverage option for a healthcare technology company between roughly 3 million and 15 million ARR that has a competent sales leader but an incoherent revenue architecture. The fractional CRO does not take the sales team away from the VP; they build the layer above it — the reimbursement roadmap, the segmentation, the compliance-aware forecast model — and hand it over. Typical engagement is two to three days a week for six to nine months.

The mistake to avoid is treating "CRO" as a promotion title for a VP of Sales who has been around a while. In healthcare tech that promotion routinely fails, because the CRO job requires conversations with health plan medical directors, hospital CFOs, and compliance officers that a career quota-carrier has never had to run. Title inflation without domain expansion produces a CRO who is really just a VP of Sales with more direct reports and a worse forecast.

How to choose between them

Choosing is a diagnostic exercise, not a preference. Work through the constraint stack in order and stop at the first layer that is broken — that layer names your hire.

Layer one: is the offer sellable at all? Do you have clinical evidence a physician champion will defend in front of a peer? Is there a reimbursement path — an existing CPT code, a value-based contract line item, a documented cost-of-care reduction — that a CFO can point at? Is your security and privacy posture packaged (SOC 2 Type II, a HIPAA risk assessment, a standard BAA, a data use agreement template)? If any of these is missing, hiring a VP of Sales is setting money on fire. Reps will generate meetings, meetings will convert to pilots, and pilots will die in legal or clinical review. This is CRO territory, and often fractional CRO territory, because the work is architectural and finite.

Layer two: is the motion repeatable? Have you closed at least six to ten deals of the same shape, in the same segment, through the same sequence of gates, with a documented path from first meeting to signed BAA to pilot to contract? If yes, you have a playbook, and a VP of Sales is the correct hire — their entire job is executing and scaling a known motion. If you have ten closed deals that each happened a different way, you do not have a playbook; you have ten anecdotes, and a VP of Sales will spend nine months discovering that.

Layer three: how many motions do you run? One motion, one segment, one buyer — a VP of Sales is sufficient and a CRO is overhead. Two or more motions with different economics — say direct health-system sales alongside a payer or employer channel — and you need a CRO, because someone has to own the allocation decision between them and no VP of Sales can arbitrate against their own quota.

Layer four: where does revenue actually leak? Pull your last twelve months of closed-lost and stalled deals and categorize the cause. If the dominant causes are pipeline coverage, discovery quality, competitive losses, and discounting, that is a VP of Sales problem. If the dominant causes are compliance review, security questionnaires, failed pilots, missing evidence, and reimbursement ambiguity, that is a CRO problem, and hiring another sales leader will not move it. This single analysis resolves most hiring debates in a healthcare technology company faster than any interview loop.

One more filter: look at who the candidate can call. A healthcare tech CRO should be able to name and reach health plan medical directors, hospital CFOs, ACO executives, and EHR partnership leads. A VP of Sales should be able to reach physician champions, service-line directors, and health system IT leadership. If your candidate's network matches the wrong list, the title on the offer letter will not fix it.

Costs, timelines, and expected impact

The economics differ enough that the choice materially changes your burn, and the timelines differ enough that the wrong choice costs you a year you cannot get back.

Compensation shape. A VP of Sales in healthcare technology is typically compensated with a base and a roughly 50/50 to 60/40 base-to-variable split, with variable driven almost entirely by new bookings against an annual quota, paid quarterly. A CRO's package skews toward a higher base with a smaller variable percentage, but the variable is measured across a broader basket: new ARR, net revenue retention, gross margin, and often qualitative gates tied to compliance posture or partnership milestones. Both roles carry equity, with the CRO's grant generally larger and more heavily weighted to multi-year performance because the outcomes they own take multiple years to materialize. Exact figures vary widely by stage, geography, and funding, so benchmark against current compensation surveys rather than anecdote.

Fractional economics. A fractional or interim CRO is usually engaged on a monthly retainer for a defined day commitment — commonly two to three days a week — with a fixed term of six to nine months and a clear deliverable set. The advantage in healthcare technology is specific: the architectural work (reimbursement roadmap, evidence strategy, segment definition, compliance-aware forecasting) is finite and front-loaded, so you are buying a project outcome rather than a permanent seat. The risk is that a fractional leader without deep healthcare domain experience produces a generic RevOps deck that ignores payer dynamics entirely.

Ramp and time-to-signal. This is where healthcare tech diverges hardest from general B2B SaaS. A new VP of Sales in this market needs six to nine months before their forecast is trustworthy, and nine to twelve months if they come from outside healthcare, because they must absorb clinical vocabulary, the regulatory landscape, EHR integration realities, and reimbursement mechanics before they can qualify a deal correctly. Judging a healthcare tech VP of Sales on a first-quarter number is judging noise. A CRO's first signal comes faster but is different in kind: within 90 days you should see a documented deal map, a compliance-aware forecast, and at least a couple of previously stalled deals moved out of legal or clinical hold.

Sales cycle reality. Enterprise health system deals in healthcare technology commonly run nine to eighteen months from first meaningful conversation to signature, and longer when a clinical pilot with a formal readout is required. Smaller community hospitals and clinic groups close faster but churn harder because they lack the implementation capacity to realize value. The practical consequence is a barbell pipeline: a handful of very large, very slow deals and a long tail of small, fast, fragile ones. Neither the VP of Sales nor the CRO can compress the regulatory clock — but the CRO can shorten it structurally by pre-clearing security reviews, publishing evidence, and getting on preferred vendor lists before a rep ever calls.

Expected impact by role. A good VP of Sales in a company with real product-market fit should measurably improve rep ramp time, win rate within qualified opportunities, and forecast accuracy — typically visible within two to three quarters. A good CRO should measurably improve the mix of pipeline that survives compliance and clinical review, net revenue retention, and average contract value through better packaging. Those show up over three to six quarters. If you need a number in ninety days, you do not have a hiring problem; you have a cash problem, and neither role solves it.

The cost of getting it wrong. Hiring a VP of Sales into a company that has not cleared layer one of the constraint stack typically burns twelve to eighteen months and the fully loaded cost of the leader plus every rep they hire, and it also burns pipeline: deals worked by an unprepared team get poisoned, and the same accounts are harder to re-enter later. Hiring an expensive full-time CRO into a company that only needed sales execution burns cash on strategy the company is not yet ready to use.

Implementation and handoff details

Whichever structure you pick, the handoff mechanics decide whether the investment compounds or evaporates. In healthcare technology the handoff artifact matters more than in almost any other category, because so much of the winning logic lives outside the CRM.

The first 30 days for a revenue leader here is an audit, not a pipeline review. Map every open deal to its regulatory and clinical stage: does it have a signed BAA, a completed security review, an executed data use agreement, a scheduled or completed pilot, a named economic buyer with an identified budget source. Most healthcare tech CRMs record none of this, which is precisely why their forecasts are fiction. The audit typically reveals that a large share of "late-stage" pipeline is actually blocked on a document nobody owns.

Days 30 to 60: rebuild the stage definitions around gates, not feelings. Healthcare tech deals advance through gates — clinical fit, technical and EHR integration feasibility, security and compliance clearance, clinical validation, financial and reimbursement validation, contracting — and each gate has a binary artifact. A stage should mean "this artifact exists," not "the rep feels good." Add a separate hold status for deals in legal or clinical review so they stop distorting coverage math; a deal that is genuinely excellent but waiting on a compliance officer's third-party audit is not a this-quarter deal regardless of its size.

Days 60 to 90: publish the two assets that unblock everyone. First, an evidence library — outcomes data, pilot readouts, peer-reviewed references where they exist, reference customers by segment — organized so a rep can answer a clinical champion without escalating. Second, a reimbursement roadmap that shows a buyer how the technology gets paid for under their actual payment model, not just what it costs. These two artifacts are the durable output of CRO-level work, and they are exactly what a VP of Sales cannot produce alone.

Operating cadence. The weekly sales forecast meeting stays with the VP of Sales. The addition in healthcare tech is a bi-weekly cross-functional deal review that includes legal or compliance, the clinical liaison or medical affairs lead, and finance — not just sales. Deals in this market die between functions, and a meeting that only contains sales people cannot see those deaths coming.

RevOps ownership. RevOps sits under the CRO when one exists, because the instrumentation has to span marketing, sales, and customer success to be useful — and because the compliance-aware fields described above are RevOps work, not sales work. Where there is no CRO, RevOps reports to the VP of Sales and will inevitably be optimized for sales reporting only, which is a reasonable trade at small scale and a serious blind spot at larger scale.

The conversion decision. For a fractional or interim CRO, the signal to convert to full-time is not a revenue number — the cycle length makes that impossible inside a single engagement. The signal is whether a repeatable playbook now exists that a VP of Sales can run without the CRO in the room, and whether previously stuck deals have moved. If after ninety days the leader is still personally negotiating individual BAAs and cannot get clinical stakeholders to attend deal reviews, you have the wrong leader, not the wrong structure.

Division of labor once both roles exist. Write it down explicitly, because ambiguity here produces the most common failure mode: two leaders both believing they own pricing. A workable default is that the VP of Sales owns quota, headcount, territories, deal execution, and forecast submission; the CRO owns pricing and packaging, segment strategy, marketing and pipeline generation, customer success and retention, partnerships, clinical and evidence strategy, and payer relationships. Escalation of any deal requiring non-standard contract terms, a custom clinical commitment, or a reimbursement-contingent structure goes to the CRO by default. That single rule prevents most of the friction between the two roles in a healthcare technology company.

Related questions

Can a VP of Sales be promoted into the CRO role in healthcare tech?

Sometimes, but only if they have already built the muscles outside direct selling — pricing, partnerships, retention, and payer or compliance fluency. Promoting purely on tenure produces a CRO who defaults to what they know: managing reps and pushing pipeline, while the architectural work goes unowned.

At what stage should a healthcare technology company hire a CRO?

Complexity, not revenue, is the trigger. When you run more than one go-to-market motion, or when deals routinely die in compliance and clinical review rather than in competitive selling, you need a CRO. Before that, a strong VP of Sales plus a fractional CRO for the architectural work is usually more efficient.

Does the CRO or the VP of Sales own customer success?

The CRO does, whenever both roles exist. In healthcare technology, renewals hinge on implementation success and demonstrated clinical or financial outcomes — decisions made by clinical and finance stakeholders, not the original buyer. Putting retention under a new-bookings-compensated VP of Sales reliably underfunds it.

How do you measure a healthcare tech VP of Sales in year one?

Use leading indicators, since the cycle outruns the fiscal year. Track deals passing the clinical validation and compliance gates, rep ramp time to first closed deal, forecast accuracy within a defined band, and pipeline created that survives qualification — not just bookings.

What if we can only afford one of the two roles?

Diagnose the binding constraint first. If the offer is validated and the motion is documented, hire the VP of Sales — throughput is your problem. If deals die on evidence, compliance, or reimbursement, buy fractional CRO capacity instead and delay the sales hire until the playbook exists.

FAQ

Does a healthcare technology company need both a CRO and a VP of Sales?

Not at every stage. Below roughly eight to twelve quota-carrying reps, one leader is usually enough — a CRO acting as player-coach, or a VP of Sales if the strategic layer is already settled. You need both when the direct engine is large enough to consume a full-time leader and you simultaneously run other motions such as channel partnerships or payer contracts. Running both too early creates an expensive layer with nothing underneath it.

How do their responsibilities differ on HIPAA and regulatory compliance?

The VP of Sales is accountable for the sales team operating compliantly — how protected health information is handled in demos and pilots, what claims reps are permitted to make, and following the approved contracting process. The CRO owns compliance as a revenue variable: how quickly security reviews clear, whether standard BAA and data use agreement templates exist, how marketing generates leads without touching regulated data, and whether pricing structures hold up under value-based contracting. One follows the rules; the other shapes how much revenue the rules cost you.

Which role owns pricing in a healthcare tech company?

The CRO, when the role exists. Healthcare technology pricing is entangled with reimbursement mechanics, value-based contract structures, implementation and integration fees, and margin exposure from services — none of which a quota-carrying VP of Sales can be neutrally accountable for. The VP of Sales should own discount authority within defined guardrails and escalate anything requiring a non-standard structure.

How do compensation structures differ between the two?

A VP of Sales carries a higher variable percentage tied almost entirely to new bookings against quota, which is appropriate for a role measured on throughput. A CRO's variable is smaller as a share of total but spans new revenue, net revenue retention, and gross margin, sometimes with gates tied to compliance or partnership milestones. In healthcare tech, where cycles run nine to eighteen months, the CRO's plan should include multi-year equity weighting so incentives match the timeline of the outcomes they own.

Can a fractional CRO work alongside an existing VP of Sales without creating conflict?

Yes, and it is one of the more effective structures at mid-scale — but only with written boundaries from day one. The fractional CRO builds the layer above the sales team: segmentation, pricing, evidence strategy, reimbursement roadmap, forecast model. The VP of Sales keeps the team, the quota, and the forecast submission. Conflict appears when the fractional leader starts running one-on-ones with reps, which signals the mandate was never scoped properly.

What background should each role have in healthcare technology?

A healthcare tech CRO should pair genuine revenue leadership with at least one adjacent domain — health plan contracting, healthcare compliance, clinical research, or provider-side finance — plus a network reaching payer and health system executives. A VP of Sales can come from another healthcare technology company that already cleared its regulatory hurdles, but must be trained on your specific compliance posture, integration requirements, and evidence base before carrying a full quota.

Sources

• https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample-business-associate-agreement-provisions/index.html
• https://www.cms.gov/priorities/innovation/models
• https://www.healthit.gov/topic/standards-technology/standards
• https://hl7.org/fhir/
• https://oig.hhs.gov/compliance/physician-education/
• https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd
• https://aicpa.org/resources/landing/system-and-organization-controls-soc-suite-of-services
• https://www.ama-assn.org/practice-management/cpt

Related on PULSE

• When to hire a fractional CRO versus a full-time revenue leader
• How to build a compliance-aware sales forecast in regulated markets
• RevOps stage definitions that survive long enterprise sales cycles
• Pricing and packaging for value-based healthcare contracts
• What net revenue retention should look like in healthcare technology
• Structuring the first 90 days for a new revenue leader